ClinicalTrials.gg
RecruitingNCT05697575REPINUpdated Apr 13, 2026

Non-immunogenic Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice

An observational study in Acute Stroke, sponsored by National Society for Neurosonology and Cerebral Circulation. Recruiting at 1 site in Russia. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Primary conditionIschemic StrokeRegistry: StrokeReclassifiedWhy we changed it
Registry
Stroke — the first condition term the registry derived for this study.
ClinicalTrials.gg
Ischemic Stroke
Why
  1. The study's title name Ischemic Stroke, a narrower term within Stroke.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by National Society for Neurosonology and Cerebral Circulation · Observational

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Other
Enrollment
336
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Ischemic Stroke with a site in Russia — 13 open to participants now, 13 under way, 2 of them phase 3. Ischemic Stroke · Russia.

Started
2023
the only one that year
Observational
8 of 17
5 open now
Primary completion
2030-02
later than 11 of 12 live
Registered
4th of 17
by date
Lead sponsor
1 of 17
National Society for Neurosonology and Cerebral Circulation

Among the 17 studies in Ischemic Stroke with a site in Russia, this one is the only one that started in 2023, is one of 8 observational ones, reaches primary completion later than 11 of the 12 other live ones, and was the 4th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

13 of the 17 studies in Ischemic Stroke with a site in Russia are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Ischemic Stroke with a site in Russia, or all of them as a file.
02

Study summary

The study will collect data from aged 18 to 85 years with a diagnosis of acute stroke, who received thrombolytic treatment with a new agent, nonimmunogenic staphylokinase. Outcomes will be checked for safety and compared to the results of treatment with the other thrombolytic drug, alteplase.

03

Conditions studied

  • Acute Stroke

Browse trials for

Keywords

  • stroke thrombolysis
  • acute ischemic stroke
  • reperfusion
04

In context

Ischemic Stroke Reclassified

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

This study's planned enrollment of 336 is above the median of 300 across 776 observational studies indexed under Ischemic Stroke.

Browse Ischemic Stroke studies →

Lead sponsor

This is the only study on the registry with National Society for Neurosonology and Cerebral Circulation as lead sponsor.

Compared within Ischemic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Men and women aged 18 to 85 years (inclusive), who meet the inclusion criteria and do not have contraindications for thrombolysis, with a diagnosis of acute ischemic stroke.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-85 ;
  • Diagnosis of acute ischemic stroke eligible for thrombolytic therapy;
  • Thrombolytic therapy with the drug "non-immunogenic staphylokinase" is planned or has already been performed.

Exclusion criteria

Exclusion Criteria:

  • Individual intolerance or known to a recombinant protein containing the amino acid sequence of staphylokinase;
  • The presence of a to thrombolytic therapy of ischemic stroke;
  • Pregnancy or lactation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Observational model
Case-only
Time perspective
Other
Enrollment
336 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
07

What researchers measure

Primary outcomes

  1. Proportion of intracerebral hemorrhage

    Number and proportion of intracerebral bleeding of any type, which occurs as a complication of thrombolytic treatment

    Time frame: 36 hours

08

Study locations

1 of 1 sites recruiting
  • St. Petersburg Research Institute of Emergency Medicine named after I.I. Janelidze
    Saint Petersburg, Russia
    Recruiting
    • Ekaterina Gogoleva · Contact
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Feb 2030, 84 months after the start.

Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 84 months is above that.

Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2023
First posted
Jan 26, 2023
StartActual
Feb 1, 2023
Primary completionEst.
Feb 1, 2030
CompletionEst.
May 10, 2030
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05697575
Lead sponsor
National Society for Neurosonology and Cerebral Circulation
Responsible party
Sponsor
First posted
Jan 26, 2023
Start date
Feb 1, 2023
Primary completion
Feb 1, 2030 (estimated)
Completion
May 10, 2030 (estimated)
Last update
Apr 13, 2026

Study contacts

Tatiana Kharitonova
Contact
tvh2001@mail.ru
+79217450431
Igor A Voznjuk, Prof
study director · First St. Petersburg State Medical University named after I.P. Pavlov

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion